DUPLIVIR® is contraindicated in patients with previously demonstrated hypersensitivity to any of the product’s components.
As this is a tablet containing the combination of lamivudine and tenofovir disoproxil fumarate, DUPLIVIR® should not be co-administered with other drugs containing lamivudine or tenofovir disoproxil fumarate. Due to the similarities between emtricitabine and lamivudine, DUPLIVIR® should also not be co-administered with products containing emtricitabine. There is interaction between zalcitabine and laminudin, therefore coadministration of zalcitabine and DUPLIVIR® is not recommended.
DUPLIVIR® should not be coadministered concomitantly with drugs based on adenofovir dipivoxil.
It is not recommended to use DUPLIVIR® as a component of a three-nucleoside administration program.
Patients with renal insufficiency should not use DUPLIVIR®, because dose adjustment is not possible.
There are no age-related contraindications; however, safety and efficacy in pediatric patients under 18 years of age have not been established.